As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Open original source
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Open original source